Successful epoprostenol withdrawal in pulmonary arterial hypertension: Case report and literature review

Respiratory Care

Volumn 58, Issue 2, 2013, Pages

  Demerouti, Eftychia A ^a   Manginas, Athanassios N ^b   Athanassopoulos, George D ^a   Karatasakis, George T ^a   Leontiadis, Evangelos D ^a   Pavlides, Gregory S ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b Mediterraneo Hospital   (Greece)

Author keywords

Prostanoids; Pulmonary hypertension

Indexed keywords

ACENOCOUMAROL; BOSENTAN; PROSTACYCLIN; SILDENAFIL;

ADULT; ARTICLE; CASE REPORT; CATHETER INFECTION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HEART CATHETERIZATION; HEART INDEX; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; LUNG WEDGE PRESSURE; MEAN ARTERIAL PRESSURE; PHYSICAL EXAMINATION; PULMONARY HYPERTENSION; THORAX RADIOGRAPHY;

ACENOCOUMAROL; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; PIPERAZINES; PURINES; SULFONAMIDES; SULFONES; VASODILATOR AGENTS; WITHHOLDING TREATMENT;

EID: 84873633748     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.01752     Document Type: Article

References (33)

1. Forfia PR, McLaughlin VV. Pulmonary hypertension. In: Claude Lenfant, editor. Medical treatment of PAH: prostacyclins. Lung Biology in Health and Diseases, Vol 236. Bethesda, MD: Informa; 2009:340-341.
2. Barst RJ. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart 1997;77(4):299-301.
3. Jones DK, Higenbottam W, Wallrork J. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). Br Heart J 1987;57(3):270-278.
4. Falk A, Lookstein RA, Mitty HA. Flolan infusion interruption: a lethal complication during venous access. J Vasc Interv Rasdiol 2001;12(5):667-668.
5. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336(2):111-117.
6. Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess 2009;13(49):1-320.
7. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003;2(2):123-127.
8. Diaz-Guzman E, Heresi GA, Dweik RA, Minai OA. Long-Term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension. Respir Med 2008;102(5):681-689.
9. Keogh A, Jabbour A, Weintraub R, Brown K, Hayward C, Macdonald P. Safety and efficacy of transition from subcutaneous treptostinil to oral sildenafil in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2007;26(11):1079-1083.
10. Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM. Long-Term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. J Heart Lung Transplant 2007;26(4):363-369.
11. Steiner MK, Preston IR, Klinger Criner GJ, Waxman AB, Farber HW, Hill NS. Conversion to bosentan from prostacyclin infusion therapy in PAH: a pilot study. Chest 2006;130(5):1471-1480.
12. Suleman N, Frost AE. Transition from epoprostenol and treptostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 2004;126(3):808-815.
13. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of longterm epoprostenol therapy for pulmonary arterial hypertension. Chest 2003;124(4):1612-1615.
14. Hoeper MM, Welte T. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2006;354(10):1091-1093.
15. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107(2):216-223.
16. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective study. Ann Intern Med 1991;115(5):343-349.
17. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982;66(2):334-338.
18. Galie N, Manes A, Negro L, Palazzini M, Bacchi Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30(4):394-403.
19. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334(5):296-302.
20. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112(7):485-491.
21. McLaughlin VV, Shillington RN, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-1482.
22. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40(4):780-788. Article in Spanish.
23. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30(2):343-349.
24. Sakuma M, Demachi J, Nawata J, Suzuki J, Takahashi T, Shirato K. Long term epoprostenol therapy in PAH. Circ J 2009;73(3):523-529.
25. Conte JV, Gaine SP, Orens JB, Harris T, Rubin LJ. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant 1998;17(7):679-685.
26. Safdar Z. Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan. Respir Med 2009; 103(11):1688-1692.
27. Escribano Subías P, Cea-Calvo L, Tello de Menesses R, Gómez Sánchez MA, Delgado Jiménez JF, Sáenz de la Calzada C. Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension. Rev Esp Cardiol 2003;56(8):818-821.
28. Rubenfire M, McLaughlin V, Allen RP, Elliott G, Park MH, Wade M, Schilz R. Transition from iv epoprostenol to subcutaneous treptostinil in pulmonary arterial hypertension. Chest 2007;132(3):757-763.
29. Vachiery JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from iv epoprostenol to subcutaneous treptostinil in pulmonary arterial hypertension. Chest 2002;121(5):1561-1565.
30. Sitbon O, Manes A, Jais X, Pallazini M, Humbert M, Presotto L, et al. Rapid switch from intravenous epoprostenol to intravenous treptostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 2007;49(1):1-5.
31. Gomberg-Maitland M, Tapson VF, Benza RL, Mc Laughlin VV, Krickman, Widlitz AC, Barst RJ. Transition from intravenous epoprostenol to intravenous treptostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005;172(12):1586-1589.
32. Melnick L, Barst RJ, Rowan CA, Kerstein D, Rosenzweig E. Effectiveness of transition from intranenous eporpsotenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. Am J Cardiol 2010;105(10):1485-1489.
33. Petkov V, Ziesche R, Mosqoeller W, Schenk P, Vonbank K, Stiebellhner L, et al. Aerolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 2001;56(9):734-736.